Clinical trial results for
esophageal or gastroesophageal junction
cancer after surgery
Esophageal or gastroesophageal junction
(GEJ) cancer that has been treated with
chemoradiation followed by surgery to help
prevent it from coming back
Clinical trial results for
esophageal or gastroesophageal junction
cancer after surgery
Esophageal or gastroesophageal junction
(GEJ) cancer that has been treated with
chemoradiation followed by surgery to help
prevent it from coming back
Actor portrayals.
OPDIVO is not approved for people younger
than 18 years of age.
In a clinical trial of 794 people who had received chemoradiation followed by surgery to remove their esophageal or GEJ cancer, 532 people were given OPDIVO and 262 people were given placebo.
Half the people remained free of their cancer returning
Half the people remained free of their cancer returning
People given OPDIVO after chemoradiation and surgery had a 31% lower risk of their esophageal or GEJ cancer returning compared to people given placebo.
OPDIVO will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults with esophageal or gastroesophageal junction (GEJ) cancer who have been treated with chemoradiation followed by surgery to help prevent it from coming back
OPDIVO® (nivolumab) is a prescription medicine that may be used in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.